Endometrial hyperplasia epidemiology and demographics: Difference between revisions

Jump to navigation Jump to search
(Mahshid)
No edit summary
Line 10: Line 10:
*Women of all age groups may develop endometrial hyperplasia.<ref name=lk>Endometrial Hyperplasia. Radiopedia. http://radiopaedia.org/articles/endometrial-hyperplasia-1 Accessed on March 9, 2016</ref>.
*Women of all age groups may develop endometrial hyperplasia.<ref name=lk>Endometrial Hyperplasia. Radiopedia. http://radiopaedia.org/articles/endometrial-hyperplasia-1 Accessed on March 9, 2016</ref>.
*However, endometrial hyperplasia is more common in [[postmenopausal]] women.
*However, endometrial hyperplasia is more common in [[postmenopausal]] women.
Most patients (75%) with endometrial cancer present with postmenopausal bleeding; however, only 10% of women with postmenopausal bleeding have endometrial carcinoma.28 The remaining women with postmenopausal bleeding have atrophic or inactive endometrium or benign endometrial conditions such as polyps. The clinical predictive model proposed by Feldman and colleagues30 (i.e., 70 years of age or older, diabetes, nulliparity, and postmenopausal status) is not predictive enough to distinguish between women with perimenopausal or postmenopausal bleeding at low versus high endometrial carcinoma risk.31 The traditional risk indicators associated with EIN/carcinoma are shown in Table 2. Most of the indicators are estrogen related, either from endogenous or exogenous sources. In women with these risk factors, the relative risk of developing carcinoma is 1.2–35.32 Experience also suggests that a significant proportion of patients fail to have these risk indicators but develop endometrial carcinoma. In these cases, either the disease may not be hormone related, or hyperestrogenism is metabolically inapparent. In a literature review, 74% of patients with adenocarcinoma of the endometrium were not obese, 58% were not nulliparous, 22% experienced menopause before age 49 years, and 43–89% were not exposed to hormone replacement therapy (HRT).33 It seems that the only constant endometrial carcinoma risk indicator is age. In women aged 65 years or older, endometrial cancer is generally aggressive and has a high mortality rate (75%) compared with that (15%) in the younger age group with hormone-related cancer.34


==References==
==References==

Revision as of 20:25, 8 February 2019

Endometrial hyperplasia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Endometrial hyperplasia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Case Studies

Case #1

Endometrial hyperplasia epidemiology and demographics On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Endometrial hyperplasia epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Endometrial hyperplasia epidemiology and demographics

CDC on Endometrial hyperplasia epidemiology and demographics

Endometrial hyperplasia epidemiology and demographics in the news

Blogs on Endometrial hyperplasia epidemiology and demographics

Directions to Hospitals Treating Endometrial hyperplasia

Risk calculators and risk factors for Endometrial hyperplasia epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Soujanya Thummathati, MBBS [2]

Overview

Women of all age groups may develop endometrial hyperplasia.[1] However, endometrial hyperplasia is more common in postmenopausal women.

Epidemiology and Demographics

Age

  • Women of all age groups may develop endometrial hyperplasia.[1].
  • However, endometrial hyperplasia is more common in postmenopausal women.

Most patients (75%) with endometrial cancer present with postmenopausal bleeding; however, only 10% of women with postmenopausal bleeding have endometrial carcinoma.28 The remaining women with postmenopausal bleeding have atrophic or inactive endometrium or benign endometrial conditions such as polyps. The clinical predictive model proposed by Feldman and colleagues30 (i.e., 70 years of age or older, diabetes, nulliparity, and postmenopausal status) is not predictive enough to distinguish between women with perimenopausal or postmenopausal bleeding at low versus high endometrial carcinoma risk.31 The traditional risk indicators associated with EIN/carcinoma are shown in Table 2. Most of the indicators are estrogen related, either from endogenous or exogenous sources. In women with these risk factors, the relative risk of developing carcinoma is 1.2–35.32 Experience also suggests that a significant proportion of patients fail to have these risk indicators but develop endometrial carcinoma. In these cases, either the disease may not be hormone related, or hyperestrogenism is metabolically inapparent. In a literature review, 74% of patients with adenocarcinoma of the endometrium were not obese, 58% were not nulliparous, 22% experienced menopause before age 49 years, and 43–89% were not exposed to hormone replacement therapy (HRT).33 It seems that the only constant endometrial carcinoma risk indicator is age. In women aged 65 years or older, endometrial cancer is generally aggressive and has a high mortality rate (75%) compared with that (15%) in the younger age group with hormone-related cancer.34

References

  1. 1.0 1.1 Endometrial Hyperplasia. Radiopedia. http://radiopaedia.org/articles/endometrial-hyperplasia-1 Accessed on March 9, 2016

Template:WikiDoc Sources